Print friendly version
Other Names for this Disease
- Agnogenic myeloid metaplasia
- Idiopathic myelofibrosis
- Myeloid metaplasia
- Primary myelofibrosis
See Disclaimer regarding information on this site. Some links on this page may take you to organizations outside of the National Institutes of Health.
Clinical Trials & Research for this Disease
- ClinicalTrials.gov lists trials that are studying or have studied Myelofibrosis. Click on the link to go to ClinicalTrials.gov to read descriptions of these studies.
- The Myeloproliferative Disorders Research Consortium (MPD-RC) is an international, multi-institutional non-profit consortium funded by the National Cancer Institute (NCI) at the National Institutes of Health and set up to coordinate, facilitate, and perform basic and clinic research investigating the genetics of MPDs with the goal of developing therapy. To learn more, click on the link.
Medical ProductsThe medication(s) listed in the table(s) below have been approved by the Food and Drug Administration (FDA) for treatment of this condition. The FDA Office of Orphan Products Development designates "orphan products" for those that treat rare diseases affecting fewer than 200,000 Americans. The table(s) below may not be an exhaustive list of drugs or products used to treat this condition. There may be other products available that are not considered orphan products. To search for all FDA approved drugs, visit Drugs@FDA. You can find orphan products used to treat other conditions by searching the Orphan Drug Product Designation database.
|Generic Name||Ruxolitinib Phosphate|
The FDA has approved this product to be used in this manner.
|Treatment of patients with intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis.|
|More Information about this product||
Drug Information Portal
Medline Plus Health Information